Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Dramatic fate of a young coronary heart disease patient rescued with specific lipoprotein(a) apheresis. J Clin Apher 2015 Jun;30(3):193-5

Date

09/03/2014

Pubmed ID

25181645

DOI

10.1002/jca.21356

Scopus ID

2-s2.0-84930854418 (requires institutional sign-in at Scopus site)   2 Citations

Abstract

Lipoprotein(a) [Lp(a)] is acknowledged to be an independent atherothrombotic risk factor. Although genetic studies have highlighted the causal relationship between coronary disease and Lp(a), it is uncertain which strategies maximize the therapeutic benefit of patients with high Lp(a) levels. We report the challenging case of a young coronary heart disease (CHD) patient who underwent 10 percutaneous coronary interventions due to repeated acute coronary syndromes (2006-2009) despite an optimally controlled, traditional risk-factor profile. For the first time, we performed specific Lp(a) immunoadsorption in the presence of very low levels of low-density lipoprotein cholesterol (LDL-C) while the patient was on a high-dose statin regimen. There have been no previous reports of patients with high Lp(a) levels who achieved LDL-C goals when treated with an isolated Lp(a)-lowering method. Despite the very high risk of cardiovascular death, targeting Lp(a) resulted in dramatic improvement of the patient's clinical condition. Thus, we suggest that specific Lp(a) apheresis should be considered an effective new treatment strategy for patients with progressive CHD who have reached LDL-C goals but harbor elevated Lp(a) levels.

Author List

Safarova MS, Ezhov MV, Afanasieva OI, Konovalov GA, Pokrovsky SN

Author

Maya Safarova MD, PhD Assistant Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adult
Blood Component Removal
Cholesterol, LDL
Coronary Disease
Disease Progression
Humans
Lipoprotein(a)
Male
Risk Factors
Treatment Outcome